Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis

• Published in: Critical care (London, England) Vol. 22; no. 1; pp. 146 - 3
• Main Authors: Banerjee, Debasree, Monaghan, Sean, Zhao, Runping, Walsh, Thomas, Palmisciano, Amy, Phillips, Gary S., Opal, Steven, Levy, Mitchell M.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07.06.2018; BioMed Central; BMC
• Subjects: Apoptosis; Cardiovascular disease; Care and treatment; Cell death; Chronic obstructive pulmonary disease; Critical care; Cytokines; E coli; Emergency medical care; Family medical history; Gangrene; Hospitals; Immunotherapy; Intensive care; Letter; Ligands; Lymphocytes; Mortality; Pancreatitis; Proteins; Sepsis; Soluble programmed cell death ligand-1; Soluble programmed cell death protein-1; Staphylococcus infections; Tumor necrosis factor-TNF; Rhode Island; United States > US; Ohio; Soluble programmed cell death protein-1; Sepsis; Soluble programmed cell death ligand-1

Immunotherapy targeting the programmed cell death protein-1 (PD-1)–programmed cell death ligand-1 (PDL-1) axis in sepsis is poised for clinical trials, although optimal inclusion criteria and predictors of response are not well characterized. Soluble PD-L1 outperforms sPD-1 for discrimination of sep...